The SAFFRON data is a major derisking event for ORPATHYS' global approval pathway, significantly increasing the probability of regulatory submissions in the US and EU. Traders should monitor for upcoming medical meeting presentations and regulatory filing announcements, which could serve as additional catalysts. The strong win rate (78%) on prior HCM reports supports a bullish read-through here.
Price Chart
Executive Summary
HUTCHMED announced positive Phase III SAFFRON trial results showing ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) achieved statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS) versus chemotherapy in MET-driven EGFR-mutated NSCLC patients who progressed on TAGRISSO. This is the first global Phase III trial to demonstrate both PFS and OS benefits in this setting, providing pivotal data to support global regulatory filings for the combination. The results de-risk the global registration pathway for ORPATHYS, a key pipeline asset co-developed with AstraZeneca, and address a significant unmet need in a large patient population.
Key Facts
- SAFFRON Phase III trial met primary endpoint of PFS and key secondary endpoint of OS with statistical significance vs platinum-based chemotherapy.
- Trial enrolled 338 patients across 230 centers in 29 countries.
- ORPATHYS + TAGRISSO is already approved in China based on the SACHI Phase III trial; SAFFRON data supports global registrations.
- Safety profile was consistent with known profiles of each medicine; no new safety findings.
- MET overexpression/amplification occurs in ~34% of tumors after progression on third-generation EGFR TKIs, representing a large addressable market.
Financial Impact
Positive top-line Phase III data for ORPATHYS in a global registration-enabling trial; no specific revenue or deal value disclosed in the filing.
Risk Factors
- Regulatory approval timelines and outcomes in ex-China markets remain uncertain.
- Competition from other MET-targeted therapies in development.
- ORPATHYS is commercialized by AstraZeneca, limiting HUTCHMED's direct revenue capture from global sales.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001648257-26-000049 |
| Document: hcm-20260817x6k.htm | 0001648257-26-000049 |
| Document: 0001648257-26-000049-index-headers.html | 0001648257-26-000049 |
| Document: 0001648257-26-000049-index.html | 0001648257-26-000049 |
| Document: 0001648257-26-000049.txt | 0001648257-26-000049 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 29d ago | 6-K | $14.11 $12.82 | ▼ −9.14% | ▼ −7.99% | $14.24 (+0.92%) |
Aug 31, 2026 4w ago | 6-K | $12.12 $13.88 | ▲ +14.52% | ▲ +14.66% | $14.24 (+17.49%) |
Aug 18, 2026 6w ago | 6-K | $12.64 $12.26 | ▼ −3.01% | ▼ −2.81% | $14.24 (+12.66%) |
Aug 17, 2026 6w ago | 6-K | $12.56 $12.18 | ▼ −3.03% | ▼ −1.83% | $14.24 (+13.38%) |
Aug 17, 2026 6w ago | Press Release | $12.56 $12.18 | ▼ −3.03% | ▼ −1.83% | $14.24 (+13.38%) |
Jul 30, 2026 9w ago | 6-K | $10.77 $11.83 | ▲ +9.84% | ▲ +6.22% | $14.24 (+32.22%) |
Jul 2, 2026 13w ago | 6-K | $11.44 $10.98 | ▼ −4.02% | ▼ −4.95% | $14.24 (+24.48%) |
Jun 30, 2026 13w ago | 6-K | $10.76 $11.65 | ▲ +8.27% | ▲ +7.67% | $14.24 (+32.34%) |
Jun 30, 2026 13w ago | Press Release | $10.76 $11.65 | ▲ +8.27% | ▲ +7.67% | $14.24 (+32.34%) |
Jun 29, 2026 13w ago | 6-K | $10.71 $11.65 | ▲ +8.78% | ▲ +7.39% | $14.24 (+32.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access